Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: A phase II study by the arbeitsgemeinschaft medikamentöse tumortherapie

Haematologica

Volumn 98, Issue 2, 2013, Pages 264-268

  Troch, Marlene ^a,b   Kiesewetter, Barbara ^b   Willenbacher, Wolfgang ^c   Willenbacher, Ella ^c   Zebisch, Armin ^d   Linkesch, Werner ^d   Fridrik, Michael ^e   Müllauer, Leonhard ^f   Greil, Richard ^a   Raderer, Markus ^b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Department of Internal Medicine I   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e KEPLER UNIVERSITY HOSPITAL   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; PARACETAMOL; RITUXIMAB; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; COLONOSCOPY; DIARRHEA; DRUG ACTIVITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR; HERPES ZOSTER; HUMAN; HYPERTENSION; KIDNEY FAILURE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; THROMBOCYTOPENIA; CANCER STAGING; CLINICAL TRIAL; LYMPHOMA, B-CELL, MARGINAL ZONE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 84875288790     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.072587     Document Type: Article

References (21)

1. Pileri SA, Milani M, Fraternali-Orcioni G, Sabattini E. From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities? Ann Oncol. 1998;9(6):607-12
2. Raderer M, Wöhrer S, Streubel B, Troch M, Turetschek K, Jäger U, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol. 2006;24(19):3136-41
3. Thieblemont C, Bastion Y, Berger F, Rieux C, Salles G, Dumontet C, et al. Mucosaassociated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behaviour: analysis of 108 patients. J Clin Oncol. 1997;15(4):1624-30
4. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, Boot H, Du MQ, Megraud F, et al. EGILS consensus report. Gastric extranodal B-cell lymphoma of MALT. Gut. 2011;60(6):747-57
5. Jäger G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, et al. Treatment of extranodal marginal zone Bcell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002;20(18):3872-7
6. Sigal DS, Miller HJ, Schram ED, Saven A. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood. 2010;116(16):2884-96
7. Raderer M, Jäger G, Brugger S, Püspök A, Fiebiger W, Drach J, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology. 2003;65(4):306-10
8. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition ISBN-13 9789283224310
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47
10. Copie-Bergman C, Gaulard P, Lavergne-Slove A, Brousse N, Fléjou JF, Dordonne K, et al. Proposal for a new histological grading system for posttreatment evaluation of gastric MALT lymphoma. Gut. 2003; 52(11):1656
11. Troch M, Kiesewetter B, Dolak W, Jaeger U, Püspök A, Müllauer L, et al. Plasmacytic differentiation in MALT lymphomas following treatment with rituximab. Ann Hematol. 2012;91(5):723-8
12. Cervetti G, Galimberti S, Sordi E, Buda G, Orciuolo E, Cecconi N, et al. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010;21(4):851-4
13. Orciuolo E, Buda G, Sordi E, Baraté C, Galimberti S, Ciancia E, et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res. 2010;34(2):184-9
14. Püspök A, Raderer M, Chott A, Dragosics B, Gangl A, Schöfl R. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Gut. 2002;51(5):691-4
15. Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the firstline, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009;115(22):5210-7
16. Lévy M, Copie-Bergman C, Molinier-Frenkel V, Riou A, Haioun C, Gaulard P, et al. Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up. Leuk Lymphoma. 2010;51(2):284-90
17. Rigacci L, Nassi L, Puccioni M, Mappa S, Polito E, Dal Pozzo S, et al. Rituximab and chlorambucil as first-line treatment for lowgrade ocular adnexal lymphomas. Ann Hematol. 2007;86(8):565-8
18. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, Ye H, Molina T, Bouhnik Y, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357(9249):39-40
19. Van Den Neste E, Louviaux I, Michaux JL, Delannoy A, Michaux L, Hagemeijer A, et al. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2'-deoxyadenosine. Br J Haematol. 1999;105(1):268-70
20. Jäger G, Höfler G, Linkesch W, Neumeister P. Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chlorodeoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica. 2004;89(4):ECR01
21. Ogura M, Morishima Y, Kobayashi Y, Uike N, Sugai S, Chou T, et al. Cladribine Study Group. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. Int J Hematol. 2004;80(3):267-77.